ABSI vs RXRX
ABSI: Absci is an AI-native biopharmaceutical company shortening the timeline and cost of antibody discovery by integrating generative design with rapid lab validation. RXRX: Recursion Pharmaceuticals is a TechBio company using proprietary AI-driven platforms and supercomputing to fundamentally transform the drug discovery and development process.
Side-by-side fundamentals
| Metric | ABSI | RXRX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $8.94 | $3.95 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $1.5B | $2.1B | |
| Net margin | -2274.1% | -863.4% | RXRX higher |
| Operating margin | -2401.6% | -867.9% | RXRX higher |
| ROE FY2025, SEC XBRL | -60.8% | -57.0% | RXRX higher |
| ROA FY2025, SEC XBRL | -53.3% | -43.7% | RXRX higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.02 | ABSI lower |
| Revenue growth (YoY) as of 2026-09-03 | -61.9% | -15.1% | RXRX higher |
| Revenue CAGR (3y) SEC XBRL | -1.8% | +23.3% | RXRX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.31 | 2.56 | |
| 1-year return as of 2026-10-08 close | +113.9% | -35.1% | ABSI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.